Kornimate/medical-research-clean huggingface dataset:
effects of autogenic and reciprocal inhibition, muscle energy techniques in the management of mechanical neck pain

Conditions: Neck Pain

Summary: neck pain is among the most common musculoskeletal disorders worldwide and is an important public health issue in terms of personal wellbeing. prevalence of neck pain show excessive variations, with a point prevalence varying between 6% and 22%, and one year prevalence ranging between 1.5-75%. neck pain like all other mechanical disorders leads to pain, disability and decreased range of motion (rom). stretching is a very common exercise performed by sportsmen, elderly, in physical therapy and rehabilitation patients, thus practiced in all sorts of fitness programs. the major types of stretching included in the literature are static, dynamic and pre-contraction stretching; of which static stretching is the conventional type of stretching. the different types of pre-contraction stretching include proprioceptive neuromuscular facilitation (pnf) stretching, post isometric relaxation (pir), post facilitation stretch (pfs) and active isolated stretch (ais). pre-contraction stretching is also considered a part of muscle energy technique (met). recently met and pre-contraction stretching have been shown to have significant superiority over conventional stretching in management of mechanical neck pain, but the evidence is currently lacking regarding which of the two pre-contraction stretching protocols, namely autogenic and reciprocal inhibition is more effective than the other. a rct will be conducted in order to find and compare the effectiveness of conventional stretching and pre-contraction stretching (autogenic inhibition and reciprocal inhibition). one control group (conventional group) and two experimental groups (experimental group a - autogenic inhibition \& experimental group b - reciprocal inhibition) will be formed. the participants will be recruited in the study if they meet the inclusion criteria using consecutive sampling from fauji foundation hospital and randomized into the three respective groups. all the groups will receive the gold standard treatment for chronic neck pain including mobilization and modalities. in addition to the gold standard treatment the participants will receive specific stretching protocol based on their interventional group


Eligibility criteria:
inclusion criteria: 1. age 18 to 70 years; 2. neck pain on nprs 4 to 8 (moderate cases); 3. subacute or chronic cases (4 to 12 weeks). 4. decreased or painful cervical range of motion (crom) exclusion criteria: 1. signs of serious pathology (e.g., malignancy, inflammatory disorder, infection); 2. history of cervical spine surgery in previous 12 months; 3. history of trauma or fractures in cervical spine; 4. signs of cervical radiculopathy or myelopathy; and 5. vascular syndromes such as vbi

Keywords: muscle energy techniques autogenic inhibition reciprocal inhibition stretching range of motion muscle strength vas neck disability index ndi
uses of irradiated human amniotic membrane in the treatment of dystrophic epidermolysis bullosa patients

Conditions: Epidermolysis Bullosa; Chronic Skin Ulcer

Summary: to evaluate the effect of human amniotic membrane as a weekly dressing on chronic wounds in epidermolysis bullosa (eb) patients.

dried human amniotic membrane dressing were obtained from national center for radiation research and technology, egypt (ncrrt), under commercial name rege pro.

Eligibility criteria:
inclusion criteria: 1- patients diagnosed as eb wounds must be chronic exclusion criteria: 1. patients must stop other line of treatment 2. exclude patients have: 1. autoimmune diseases 2. diabetes

Keywords: epidermolysis bullosa amniotic membrane
pioglitazone and lumbar bone marrow fat in chronic kidney disease

Conditions: Polycystic Kidney Diseases

Summary: chronic kidney disease (ckd) is associated with bone changes and very high fracture rates. a component of bone is marrow. bone marrow fat is increased in patients with ckd compared to those in the normal population of the same age. it is not clear if there will be changes in the marrow fact content in those with ckd on pioglitazone. in people with normal kidney function, thiazolidinedione group of drugs have had variable effects on bone marrow fat content, as measured by mrs. this is important as changes in marrow fat are likely related to changes in the bone in patients with chronic kidney disease.

if patients consent to participate in the ancillary study of marrow fat changes with pioglitazone, those that are randomized to placebo or 15 mg pioglitazone for 12 months (per the criteria in the main study) will also undergo magnetic resonance spectroscopy (mrs) of the lumbar spine at l1, l2 and l3. mr spectroscopy of the lumbar spine (if they choose as this is ancillary study) will be performed 3 times over the course of the study.

Eligibility criteria:
inclusion criteria: * included subjects will be those who consent to the study of pioglitazone in adpkd (protocol number 1308084213). therefore inclusion and exclusion criteria are the same as for that study. subjects will not be offered participation in the bone marrow fat study till after they consent for the fda approved study. subjects who withdraw from the fda approved study will be withdrawn from this protocol. inclusion/exclusion criteria for nct#02697617 * male or female adpkd patients aged 18-55 * egfr at or above ≥ 50 ml/min/1.73 m2 by 4 parameter mdrd or ckd-epiformulas * normal liver enzymes (alt/ast) * fasting blood glucose between 70 and120 * for female patients, a willingness to use double contraception to avoid pregnancy while in study * able to give informed consent * in the opinion of the investigator, high likelihood of progressive kidney disease exclusion criteria: * diabetes, defined as any of the following: fasting blood sugar \> 130 times two, hgba1c \> 7, on any blood sugar lowering medication, or past diagnosis of diabetes not occurring during pregnancy * uncontrolled hypertension, defined as systolic \> 150, diastolic \> 90 despite an attempt by physician to titrate medications * history of impaired systolic function (ejection fraction \< 50%) by previous echo or known ischemic cardiovascular disease * findings suggestive of a kidney disease other than adpkd * systemic illness requiring immunosuppressive or anti-inflammatory agents * congenital absence of a kidney or history of a total nephrectomy * history of cyst reduction or partial nephrectomy * history of renal cyst aspiration within the previous year * history of bladder cancer, or gross hematuria * inability to undergo mri due to implantable devices or foreign objects that preclude mri * active renal transplant * allergy or sensitivity to any of the components of the test materials * institutionalized * currently pregnant or plans to become pregnant during the study
executive function and symptom reduction in youth receiving home-based treatment with collaborative problem solving

Conditions: Child Behavior; Problem Behavior; Executive Dysfunction

Summary: in this project, the investigators will extend prior results of parent-reported executive function growth and symptom reduction in children receiving home-based treatment with the collaborative problem solving treatment approach (cps), with a particular focus on examining children who have attention deficit hyperactivity disorder (adhd). the investigators will examine executive functioning (ef) of children who are receiving cps, measuring ef with parent-report and objective computer-based tasks, at two timepoints: at the start of treatment and approximately four months later, and will collect symptoms at these plus three additional timepoints: at discharge, 6-months after discharge, and 12-months after discharge.


Eligibility criteria:
inclusion criteria: * clients of participating non-profit organization that are receiving home-based youth mental health care * speaking and writing english at level necessary to complete study requirements exclusion criteria: * youth is in full state custody and consent cannot be obtained by a guardian * youth and/or guardians do not speak english well enough to complete standardized measures * youth has a confirmed or suspected full scale iq below 70, or carries a prior diagnosis of autism spectrum disorder at the moderate or severe level

Keywords: executive functioning adhd behavior problems youth cps collaborative problem solving disruptive behavior parenting
refractory ihca and ohca treated with ecmo

Conditions: Cardiac Arrest

Summary: extracorporeal membrane oxygenation (ecmo) support has been suggested to improve the survival rate in patients with refractory cardiac arrest (ca). recent studies have also highlighted the potential early application of this method in improving the prognosis of prolonged cardiac arrest both for in hospital ca (inhca) and out of hospital ca (ohca). the rationale for use of ecmo in these patients is to optimize early perfusion of vital organs, curing the cause of ca and waiting for the recovery of the injured myocardium. the investigators have created a flow-chart to decide which patients are eligible. the aims of this study are to evaluate if, with this flow-chart, the investigators are able to detect which patients have more probability of survival.


Eligibility criteria:
inclusion criteria: * adults 18-75 years old * in and out of hospital witnessed cardiac arrest * no-flow time \< 5 min. or vf,vt,tp as rhythm of presentation * low-flow time \< 45 min. * end tidal co2 \> 10 after 20 min.of cpr exclusion criteria: * comorbidities such: * terminal malignancy * aortic dissection * severe cardiac failure without transplant indication * severe aortic valve failure * known severe peripheral arteriopathy
ketamine + cognitive training for suicidality in the medical setting: pilot

Conditions: Suicide, Attempted

Summary: this project seeks to identify the acute and longer-term impact of a single dose of intravenous ketamine among suicidal patients referred for psychiatric consultation/liaison in the medical inpatient setting. the investigators will then test whether ketamine's rapid effects can be extended by introducing helpful information delivered by a computer-based training protocol. this work could ultimately lead to the ability to treat suicidality more efficiently and with broader dissemination by rapidly priming the brain for helpful forms of learning.

note: in the course of this pilot study, both the primary and secondary outcome measures were supplemented to provide additional, complementary information on the clinical effects of the study interventions, based on confirmation (through study team experience) of the feasibility of acquiring such additional information in the context of our study population, setting, and design.

Eligibility criteria:
inclusion criteria: participants will: 1. be between the ages of 18 and 65 years 2. be a medical inpatient referred for psychiatric consultation/liaison due to suicidality 3. possess a level of judgment and understanding sufficient to agree to all procedures required by the protocol and must sign an informed consent document 4. be deemed an appropriate and reasonable medical candidate for intravenous ketamine by a physician authorized to prescribe medication to the patient during inpatient hospitalization exclusion criteria: 1. presence of current psychotic or autism spectrum disorder or current delirium 2. use of a monoamine oxidase inhibitor (maoi) within the previous 2 weeks 3. current pregnancy or breastfeeding 4. reading level \<5th grade as per wrat-3 reading subtest 5. past intolerance or hypersensitivity to ketamine 6. patients taking any of the following medications: st john's wort, theophylline, tramadol, metrizamide 7. patients who have received ect in the past 6 months prior to intake 8. patients at risk for withdrawal related issues (e.g., delirium tremens, severe opiate withdrawal) or who present with substance-induced psychosis 9. patients who, based on expressed preference and/or home geographic location, are deemed by the psychiatric consultation/liaison service to be likely to receive inpatient psychiatric hospitalization at an alternate location outside of western psychiatric institute \& clinic
laparoscopic pyeloplasty registry and database

Conditions: Ureteral Obstruction

Summary: the gold standard for the treatment of ureteropelvic junction obstruction (upjo) is the open pyeloplasty. as a minimally invasive alternative, many centers are currently offering laparoscopic pyeloplasty (lp) as primary therapy for upjos. recent data has shown that laparoscopic pyeloplasty has comparable success rates to open pyeloplasties and produces durable results. the researchers are compiling a registry and database to review outcomes of laparoscopic pyeloplasty patients.


Eligibility criteria:
inclusion criteria: * male or female patients of methodist urology in indianapolis, in over the age of 18 with ureteropelvic junction obstruction exclusion criteria: * patients unable to give informed consent * patients with active bleeding diatheses * women who are pregnant or in whom pregnancy status cannot be confirmed * patients with medical conditions precluding laparoscopy * patients with active urinary tract infection

Keywords: upj obstruction renal obstruction delayed renal flow
health promotion in the elderly--prevention of cardiovascular disorders

Conditions: Cardiovascular Diseases; Heart Diseases; Cerebrovascular Disorders

Summary: to develop an epidemiologic model to estimate the benefits, costs and risks of disease prevention in the elderly.

design narrative: the investigators extended work they had done in modeling the health benefit of reducing risk factors for cardiovascular disease. their new model incorporating risks of importance in the elderly, including cerebrovascular disease, estimated both morbidity and mortality averted by risk reduction, and estimated the costs and risks of the interventions used to modify risk factors. the model was designed for the counseling of elderly individuals free of cardiovascular disease, and evaluated strategies for remaining disease free. it was implemented as software running on personal computers, and marketed to physicians and other health professionals who advised the elderly on medical issues. accompanying documentation was also developed to explain the assumptions and non-quantifiable aspects of the decision to adopt major lifestyle changes to reduce risk. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
microvascular and fibrosis imaging study

Conditions: Autoimmune Diseases; Sickle Cell Disease; Chronic Graft Versus Host Disease

Summary: in this study, laser doppler flowmetry (ldf), laser doppler imaging (ldi), orthogonal polarization spectral imaging (opsi), nail fold video capillaroscopy (nvc) and optical coherence tomography (oct) will be used to assess differences in microvascular function and density of oral mucosa and skin in subjects with 1) autoimmune diseases with cutaneous involvement: systemic sclerosis (ssc), morphea, dermatomyositis, cutaneous lupus and vasculitis, 2) sickle cell disease (scd) and 3) chronic graft-versus-host disease (gvhd) compared to healthy subjects. the microvascular changes will be compared to overall treatment response in patients with scleroderma and chronic gvhd as assessments will be made before and after the patients start treatment for their diseases and determine if these imaging techniques provide valuable and reproducible data when assessing a patient's response to treatment for those diseases. in addition, the application of acoustic radiation force impulse (arfi) in determining cutaneous thickness in patients with ssc, gvhd and morphea will be evaluated. the investigators hypothesize that the vascular and dermal structures are altered in patients with autoimmune disease, scd and chronic gvhd. in addition, they hypothesize that imaging modalities such as ldf, ldi, oct, nvc, opsi and arfi can quantify such structural alterations and can be used to 1) detect early disease activity, 2) quantify and assess response to therapy and 3) quantify and correlate with overall disease activity.


Eligibility criteria:
inclusion criteria: * subjects above the age of 18 who are capable of giving informed consent with one of the following conditions: scleroderma, graft vs host disease, sickle cell disease, morphea, connective tissue disease with cutaneous manifestations: cutaneous lupus, dermatomyositis, vasculitis, patients who are undergoing hsct, or patients with a diagnosis of hematologic and non-hematologic malignancies without gvhd * control patients include normal healthy controls above the age of 18 who are capable of giving informed consent. exclusion criteria: * patients who experience discomfort, will be prone to experience discomfort or cannot tolerate the position required for the imaging studies. * subjects unable to provide informed consent. * smokers, patients unable to tolerate caffeine avoidance for the day of the study.

Keywords: autoimmune diseases with cutaneous involvement systemic sclerosis scleroderma morphea dermatomyositis cutaneous lupus vasculitis sickle cell disease graft versus host disease
weight loss in chronic disease patient population

Conditions: Overweight; Obesity; Diabetes; Hypertension

Summary: this study will assess the effect of in-home tele-health monitoring on health outcomes for lsuhcsd chronic disease, overweight or obese patients diagnosed with type ii diabetes or hypertension.

this study will assess the effect of in-home tele-health monitoring on health outcomes for lsuhcsd chronic disease, overweight or obese patients diagnosed with type ii diabetes or hypertension. primary emphasis will be on assessing the effect of tele-health home monitoring combined with motivational telephone coaching on weight loss and waist circumference as compared to self-directed, home monitoring alone, and telephone coaching alone. secondary outcomes such as blood pressure, hemoglobin a1c (hba1c), fasting blood sugar, and cholesterol will be examined as well.

Eligibility criteria:
inclusion criteria: * age ≥ 18 yrs old * bmi ≥ 25 kg/m2 and waist circumference \> 40 inches (men)/ 35 inches (women) * weight ≤ 500lbs * at least one of the following: * fasting blood sugar \> 100 mg/dl at any point and/or taking medications for diabetes and/or * resting blood pressure \> 130/90 mm hg at any point and/or taking medications for hypertension * not involved in regular physical activity or weight loss management programs * capable of being physically active * physically able to use in-home equipment (or presence of a household member who can assist the subject in equipment use) * currently-working conventional telephone line at primary residence * grounded electrical power supply at primary residence * have been in lsu hcsd system for 6 months and anticipate remaining in the lsu hcsd patient population for the next 6 months exclusion criteria: * a history of drug abuse in the last year, or excess alcohol consumption (40g/day)6 * currently dieting or engaging in any activity with the goal of losing weight * significant weight loss or weight gain in the past year (\> 50 lbs) or current use of weight loss medications * history of gastrointestinal bypass or other bariatric surgery in the last 3 years * diagnosis of congestive heart failure * under treatment for end-stage renal disease or end-stage liver disease * history of major organ transplant * history of cancers requiring treatment in the past 5 years with anything but excellent prognosis * current diagnosis of schizophrenia, bipolar disorder, or other psychotic disorders * pregnant or plan on becoming pregnant in the next 12 months. * lack support from health care provider or family members. * current member of household participating in study * factors that may limit adherence to intervention or affect conduct of the trial. * unable or unwilling to communicate with staff, to provide written informed consent, or accept the randomized assignment. * any other condition, which, in the opinion of the investigators would impede competence or compliance or possibly hinder completion of the study.

Keywords: overweight obese type ii diabetes hypertension
mfolfirinox and stereotactic radiotherapy (sbrt) for pancreatic cancer with high risk and locally advanced disease

Conditions: Pancreatic Cancer

Summary: this is a prospective, multicentre randomised, phase ii clinical trial, with randomisation 2:1 by minimisation and stratification by tumour stage, planned chemotherapy and institution.

this is a prospective, multicentre randomised, phase ii clinical trial to evaluate safety and activity of stereotactic body radiotherapy (sbrt) in addition to chemotherapy in patients with high-risk and borderline resectable pancreatic cancer (brpc) and locally advanced pancreatic cancer (lapc). high risk defined as any patient with tumour \>4cm, extrapancreatic extension or node positive disease.

Eligibility criteria:
inclusion criteria: * adults, aged between 18-75 years, with histological confirmation of pancreatic adenocarcinoma * any of the following 1. t3 (tumour \>4 cm) 2. extrapancreatic extension 3. node positive (stage iib) 4. borderline resectable pancreatic cancer, locally advanced pancreatic cancer * measurable disease according to recist v1.1 * ecog performance status 0-1 * adequate renal and haematological function * adequate hepatic function. defined as bilirubin \<1.5 x uln (upper limit of normal), ast + alt \<3.0 x uln. in patients who have had a recent biliary drainage and whose bilirubin is descending, a value of ≤ 3 x n is acceptable * study treatment planned to start within 14 days of registration * willing and able to comply with all study requirements, including treatment, timing and/or nature of required assessments * signed, written informed consent exclusion criteria: * tumour size greater than 70mm * prior abdominal radiotherapy * evidence of metastatic disease on baseline radiologic investigations * history of another malignancy within 2 years prior to randomisation, except adequately treated carcinoma-in-situ, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial transitional cell carcinoma of the bladder, or any stage 1 endometrial carcinoma. patients with a history of other malignancies are eligible if they have been continuously disease free for at least 2 years after definitive primary treatment * concurrent illness, including severe infection that may jeopardise the ability of the patient to undergo the procedures outlined in this protocol with reasonable safety * neuroendocrine pancreatic carcinoma * life expectancy of less than 3 months * pregnancy, lactation, or inadequate contraception. women must be post-menopausal, infertile, or use a reliable means of contraception. women of childbearing potential must have a negative pregnancy test done within 7 days prior to registration. men must use a reliable means of contraception * serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol

Keywords: stereotactic body radiotherapy sbrt chemotherapy radiotherapy surgery